News

Exciting New Advancements in NMIBC Treatment by Relmada

Exciting New Advancements in NMIBC Treatment by Relmada

Relmada Therapeutics Secures Key Presentation on NDV-01

Discover the 6-month follow-up from the ongoing Phase 2 trial designed to treat patients with non-muscle invasive bladder cancer (NMIBC).

With plans to further develop NDV-01—a sustained release intra-vesicular formulation of gemcitabine/docetaxel—into Phase 3 studies by mid-2026.

The focus targets high-risk NMIBC and intermediate-risk NMIBC, which together account for a substantial portion of annual NMIBC cases.

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a forward-looking clinical-stage biotechnology company dedicated to advancing therapies for oncology and central nervous system disorders, has exciting news to share. The company is preparing to showcase the significant findings from their ongoing Phase 2 study of NDV-01, particularly concentrating on the 6-month follow-up data at the Society of Urologic Oncology 26th Annual Meeting. The presentation will highlight the continuing efforts to transform the treatment landscape for NMIBC.

Dashboard of Phase 2 Study Results

Presented by Dr. Yair Lotan, Chairman of the Clinical Advisory Board at Relmada, the poster will detail essential insights pertinent to NDV-01, an innovative, sustained release treatment that integrates gemcitabine and docetaxel as a pivotal combination. This data reveals a favorable safety profile and appears to show strong efficacy in ongoing therapeutic applications.

Raj S. Pruthi, MD, Chief Medical Officer-Oncology at Relmada, expressed optimism regarding the findings, indicating that NDV-01 has the potential to deliver a transformational approach to NMIBC treatment. Emphasizing safety, convenience, and efficacy, NDV-01 is geared to offer both patients and physicians access to a ready-to-use, bladder-sparing therapeutic option that is clinically promising.

Society of Urologic Oncology Meeting Details

The poster’s details are being looked forward to by the medical community, and it bears the following critical information:

  • Title: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 6-month Complete Response Data
  • Poster Number: #143
  • Date and Time: December 4, at 2:30 PM MT

After the presentation, a copy of the poster will be available in the Events section of the Relmada website, where interested parties can delve deeper into the displayed findings and associated discussions with regulatory bodies.

Overview of NDV-01

NDV-01 is designed to be effective for treating non-muscle invasive bladder cancer by allowing a gradual release of gemcitabine and docetaxel over an extended period. This sustained-release formulation is unique in its design, allowing for better drug retention within the bladder and minimizing adverse systemic effects.

The administration process is straightforward—able to be completed in under ten minutes without the need for anesthesia or specialized equipment, thus enhancing its appeal for clinics and patients alike. The innovative nature of NDV-01 ensures that it remains patent-protected until 2038, paving the way for a robust treatment future.

Significance of the Phase 2 Study

This Phase 2 study employs a single-arm, open-label design and evaluates the safety and efficacy of NDV-01 among patients diagnosed with high-grade non-muscle invasive bladder cancer. Participants engage in a biweekly induction phase followed by monthly maintenance doses over a year, supported by thorough assessments.

The insightful results gathered thus far focus on both the safety of the treatment and overall response rates, with secondary endpoints exploring duration of response and event-free survival outcomes.

The NMIBC Context and Market Potential

NMIBC accounts for a significant percentage of bladder cancer cases, possessing high recurrence rates and limited treatment options for patients. With over 744,000 active cases nationwide, there exists a substantial opportunity for treatments like NDV-01 to fill existing gaps in the market.

By targeting high-risk and intermediate-risk cases, NDV-01 may serve as either a frontline or salvage therapy, offering hope across various NMIBC subtypes. The potential for NDV-01 exemplifies Relmada's commitment to developing comprehensive oncology solutions.

About Relmada Therapeutics

Relmada Therapeutics stands at the forefront of clinical innovation in biotechnology, with a focused strategy to pioneer groundbreaking therapies for both oncology and central nervous system disorders. Their lead candidates, including NDV-01, showcase an unwavering drive to meet significant patient needs in the current therapeutic landscape.

For further information regarding Relmada and its offerings, you can navigate to their official website.

Frequently Asked Questions

What is NDV-01?

NDV-01 is an innovative treatment being developed for non-muscle invasive bladder cancer, utilizing a sustained release formulation of gemcitabine and docetaxel.

What are the upcoming developments for Relmada Therapeutics?

Relmada plans to enter Phase 3 studies for NDV-01 in the first half of 2026, targeting NMIBC treatments.

Why is NMIBC significant?

Non-muscle invasive bladder cancer comprises a large portion of bladder cancer cases and is associated with high recurrence rates, necessitating effective treatment options.

How does NDV-01 improve treatment delivery?

NDV-01 enables gradual drug release and can be administered in a simple clinic visit without extensive equipment, enhancing patient comfort and compliance.

Where can I obtain more information about Relmada?

More detailed information is available on Relmada’s official website, showcasing their pipeline and clinical developments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

A. O. Smith's Sustainability Scorecard Has Real Teeth

Updated Category News Views 130

Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...

Continue Reading
Siteimprove Turns Accessibility Checks Into Agent Spend

Updated Category News Views 153

Accessibility work has usually been the thing teams promise to fix after the launch party is over. Siteimprove is trying to shove that discipline directly into the AI-agent workflow, announcing on November 19, 2026 that its Siteimprove.ai Accessibility Agent is available through Agentic Commerce on AWS Marketplace. The practical hook is simple enough: an AI agent can...

Continue Reading
Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 131

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 88

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
NextPlat’s 150-Patient Test Has a Long Road Ahead

Updated Category News Views 114

A strip of pills can look mundane, yet it is where this entire NextPlat pitch either earns its keep or falls apart. PharmcoRx has signed a partner pharmacy agreement with MedSure Systems for a 150-patient Medicare medication-adherence pilot in South Florida. That is a small starting line, no two ways around it. Still, the mechanics are more interesting than another vague...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 104

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Borr’s Q3 Presentation Puts Jack-Up Investors on Watch

Updated Category News Views 106

Jack-up drilling is a rough business to judge from a calendar invite, but Borr Drilling has put a useful marker in the sand. The company is scheduled to present financial results for the three and nine months ended September 30, 2026, at 09:00 New York time, or 15:00 CET, on Thursday, November 19. For holders of BORR, this is less about ceremonial webcast chatter and more...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 174

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Hexagon Agility Nets Record $100M Order from Certarus

Updated Category News Views 79

Hexagon Agility and Certarus: A Major Deal Secured There ain't nothing like landing a big fish in the business world, and Hexagon Agility just hooked a whopper. This major player in clean fuel solutions secured an order from Certarus worth a hefty $100 million. For those who keep tabs, that's Hexagon's largest order for Mobile Pipeline® modules to date, and it's all...

Continue Reading
Performance Food Group Co's Earnings: What to Expect

Updated Category News Views 111

Preparing for Performance Food Group Co's Earnings Report Performance Food Group Co PFGC is on the verge of releasing its latest quarterly earnings report. Investors are keen to know what to anticipate ahead of this significant announcement. Expectations for Earnings Performance Analysts anticipate that Performance Food Group Co will report an earnings per share (EPS) of...

Continue Reading
Innovative Collaboration Transforms Healthcare for Incarcerated Patients

Updated Category News Views 360

Innovative Partnership Shaping Correctional Healthcare Armor Health is embarking on a transformative journey in correctional healthcare through an exciting partnership with Antidote-AI, set to significantly enhance the services provided to incarcerated individuals. This collaboration brings advanced artificial intelligence (AI) capabilities to the forefront of a critical...

Continue Reading
Celebrating Innovation: A Journey Through 17 Years of Left Field Labs

Updated Category News Views 405

Left Field Labs Marks 17 Years of Innovation and Growth Left Field Labs, a creative technology agency within Stagwell (NASDAQ: STGW), celebrates its 17th anniversary with impressive revenue growth and a diverse global client base. This celebration highlights its commitment to delivering transformative digital experiences using advanced AI technologies. Transformative...

Continue Reading
Leadership Changes at Humphreys Capital Pave New Pathway

Updated Category News Views 465

Humphreys Capital's Leadership Transition Overview Humphreys Capital, a prominent institutional investment manager, has announced significant changes in its leadership team. This transition includes the appointment of Grant Humphreys as Chairman of the Board of Directors, succeeding his father, Kirk Humphreys, who will continue his involvement as Chairman Emeritus. Blair...

Continue Reading